New vaccine trains immune system to hunt down breast cancer cells

NCT ID NCT05455658

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer. The vaccine aims to teach the immune system to recognize and attack proteins found on breast cancer stem cells. The main goal is to see if the vaccine triggers a strong immune response. Participants have already completed standard treatment and are now receiving the vaccine to help prevent the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.